SCIENTIFIC HUB

Follow the evidence.

SCIENTIFIC LITERATURE · MED

Metabolomic signatures supporting clinical stratification of Parkinson disease and atypical parkinsonism.

Parkinsonism Relat Disord · 2026-06-06

DOI: 10.1016/j.parkreldis.2026.108374PMID: 42259077

Check source for accessJournal ArticleOriginal source ↗

Research overview

The text below is the source article’s original abstract under a verified reuse license. cc by

BackgroundAccurate differential diagnosis of parkinsonian syndromes remains challenging due to overlapping clinical features between Parkinson's disease (PD) and atypical parkinsonism, including progressive supranuclear palsy (PSP) and multiple system atrophy (MSA). Systemic metabolic profiling may capture disease-related biological differences beyond clinical phenotyping.ObjectivesTo investigate whether serum metabolomic signatures, analyzed through a hierarchical ensemble machine learning framework, are associated with distinct clinical phenotypes of degenerative parkinsonian syndromes.MethodsIn this prospective single-center pilot study, 134 patients with parkinsonian syndromes (PD n = 87; PSP n = 22; MSA n = 25) and 132 healthy controls were consecutively enrolled. Untargeted serum metabolomic profiling was performed using gas chromatography-mass spectrometry. A multistep ensemble classification strategy was applied to evaluate discrimination across diagnostic categories, and model interpretability was assessed using Shapley additive explanations.ResultsA total of 241 metabolites were consistently detected. Ensemble models demonstrated high internal discrimination between PD and atypical parkinsonism and satisfactory separation between PSP and MSA. Misclassifications occurred primarily at later stratification steps. Interpretability analyses identified convergent metabolic patterns across algorithms, highlighting alterations related to carbohydrate metabolism, redox balance, lipid homeostasis, and phosphate-associated pathways.ConclusionsSerum metabolomic profiles were associated with distinct clinical phenotypes of degenerative parkinsonian syndromes in this prospective pilot cohort. These findings support the biological relevance of systemic metabolic alterations in parkinsonism and provide feasibility data for future multicenter validation studies.

Scientific assessment

01

Research question

Assess the question within the original study’s scope.

02

Methods & sample

Check the source article for study design and sample details.

03

Key findings

An editorially approved findings summary is not yet published for this record.

04

Limitations

Generalizability, bias and clinical meaning require separate assessment.

Methods, samples and clinical conclusions are not inferred from bibliographic metadata.